Editorial Board — Medscape Oncology
Board Members
- Harold J. Burstein, MD, PhD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- Bruce D. Cheson, MD
- Georgetown University
Georgetown University Hospital
Washington, DC
- Georgetown University
- David J. Kerr, MD
- University of Oxford
Oxford Cancer Centre
Oxford, United Kingdom
- University of Oxford
- Mark G. Kris, MD
- Memorial Sloan-Kettering Cancer Center
Weill Cornell Medical College
New York, New York
- Memorial Sloan-Kettering Cancer Center
- Corey J. Langer, MD
- University of Pennsylvania Medical School
Abramson Cancer Center
Philadelphia, Pennsylvania
- University of Pennsylvania Medical School
- Maurie Markman, MD
- Drexel University College of Medicine
Cancer Treatment Centers of America
Philadelphia, Pennsylvania
- Drexel University College of Medicine
- John L. Marshall, MD
- Georgetown University
Washington, DC
- Georgetown University
- Kathy D. Miller, MD
- Indiana University School of Medicine
Indiana University Simon Cancer Center
Indianapolis, Indiana
- Indiana University School of Medicine
- Richard M. Stone, MD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- Nicholas J. Vogelzang, MD
- University of Nevada School of Medicine
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
- University of Nevada School of Medicine
- Louis M. Weiner, MD
- Georgetown University Medical Center
Lombardi Comprehensive Cancer Center
Washington, DC
- Georgetown University Medical Center
- John R. Wingard, MD
- University of Florida
Shands Cancer Hospital at the University of Florida
Gainesville, Florida
- University of Florida
Board Member Details
Harold J. Burstein, MD, PhD
Associate Professor, Department of Medicine, Harvard Medical School; Physician, Breast Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.
Bruce D. Cheson, MD
Professor of Medicine, Department of Hematology-Oncology; Deputy Chief, Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC
Bruce D. Cheson, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celgene; Astellas; Pharmacyclics; Gilead; Roche-Genentech; AbbVie
David J. Kerr, CBE, MD, DSc, FRCP, FMedSci
Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom
David Kerr, CBE, MD, DSc, FRCP, FMedSci, has disclosed the following relevant financial relationships:
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Oxford Cancer Biomarkers; OxOnc; Celleron Therapeutics Ltd; Cancer Care Commission
Serve(d) as a speaker or a member of a speakers bureau for: Merck-Serono
Received research grant from: Roche; Bayer
Have a 5% or greater equity interest in: Oxford Cancer Biomarkers; Celleron Therapeutics Ltd; Cancer Care Commission
Received income in an amount equal to or greater than $250 from: Oxford Cancer Biomarkers; OxOnc; Celleron Therapeutics
Mark G. Kris, MD
Professor of Medicine, Weill Cornell Medical College; Attending Physician, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
Mark Kris, MD, has disclosed the following relevant financial relationship:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca Pharmaceuticals, LP
Corey J. Langer, MD
Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania
Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Bristol-Myers Squibb Company; Pfizer Inc; Eli Lilly and Company; Genentech, Inc.; OSI Pharmaceuticals, Inc.; Merck & Co. Inc; GlaxoSmithKline; Nektar; Clovis Oncology
Served as a scientific advisor for: Bristol-Myers Squibb Company; ImClone Systems Incorporated; sanofi-aventis; Pfizer Inc; Eli Lilly and Company; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Genentech, Inc.; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Abbott Laboratories; Morphobiotek, Inc.; Biodesix; Clariant; CarisDx; Vertex; Synta Pharmaceuticals Corp.; Celegene; Boehringer Ingelheim Pharmaceuticals, Inc.; AbbVie; Clovis Oncology; Merck & Co. Inc
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; OSI Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ImClone Systems Incorporated (all curtailed as of 12/10)
Data Safety Monitoring Committee Member: Eli Lilly and Company; Amgen Inc; Synta Pharmaceuticals Corp.; Agennix; Peregrine; SWOG; Incyte Corporation
CME: Imedex; Physicians Education Resource; TRM Oncology
Maurie Markman, MD
Clinical Professor, Drexel University College of Medicine; President, Medical & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania
Maurie Markman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP
Received income in an amount equal to or greater than $250 from: Celgene; Myriad
John L. Marshall, MD
Professor, Chief, Division of Hematology-Oncology, Georgetown University, Washington, DC
John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech, Inc.; Caris; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Celgene Corporation; Taiho Pharmaceutical Co., Ltd.
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc.; Caris; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Celgene Corporation; Taiho Pharmaceutical Co., Ltd.
Received income in an amount equal to or greater than $250 from: Genentech, Inc.; Caris; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Celgene Corporation; Taiho Pharmaceutical Co., Ltd.
Kathy D. Miller, MD
Professor, Department of Medicine (Hematology-Oncology), Indiana University Simon Cancer Center; Co-Director, Breast Cancer Program, Indiana University Simon Cancer Center, Indianapolis, Indiana
Kathy D. Miller, MD, has disclosed no relevant financial relationships.
Richard M. Stone, MD
Professor of Medicine, Harvard Medical School; Director, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts
Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Received research grant from: Novartis Pharmaceuticals Corporation
Received income in an amount equal to or greater than $250 from: Amgen Inc; Abbvie; Roche; Seattle Genetics, Inc; Bristol-Myers Squibb Company; Celator
Nicholas J. Vogelzang, MD
Professor of Clinical Medicine, University of Nevada School of Medicine, University of Nevada, Las Vegas; Board of Directors, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Nicholas J. Vogelzang, MD, has disclosed no relevant financial relationships:
Serve(d) as a director, partner, employee, advisor, consultant, or trustee for: Caris Life Sciences; Roche/Genentech; Pfizer, Inc.; Exelixis; AstraZeneca Pharmaceuticals, LP
Serve(d) as a speaker or a member of a speakers bureau for: Sanofi; Exelixis; Genentech; Caris Life Sciences
Louis M. Weiner, MD
Chairman, Professor, Department of Oncology, Georgetown University Medical Center; Director, Lombardi Comprehensive Cancer Center; Director, MedStar Georgetown Cancer Institute, Georgetown University Medical Center, Washington, DC
Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Celldex Pharmaceuticals; Jounce Therapeutics; CytomX, Inc.; Immunome, Inc.; Novartis International AG; Sandoz; Forty-Seven, Inc.; Kelun Pharmaceuticlas
Has investment interests in: Celldex Pharmaceuticals; Jounce Therapeutics; Forty-Seven, Inc.
John R. Wingard, MD
Professor of Medicine, University of Florida; Director, Bone Marrow Transplant Program, Shands Hospital at the University of Florida Health, Gainesville, Florida
John R. Wingard, MD, has disclosed the following relevant financial relationships:
Received research grant from: National Institutes of Health
Received income in an amount equal to or greater than $250 from: Astellas Pharma, Inc.; Shire; UpToDate; Celgene Corporation; Merck & Co.; Ansun; Gilead Sciences, Inc.; Pluristem; Fate Therapeutics, Inc.